thallous chloride ti 201

Small moleculeapprovedImaging agent

Approved

Dec 16, 1977

Thallous chloride (also known as Thallium(I) chloride) is a chemical compound with the formula TlCl. Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for: Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 6 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1

Earliest trial started Jul 1, 2006 (NCT00381316)

Timeline

1970s

  1. Dec 16, 1977

    Lantheus Medical Imaging — Earliest FDA Approval

  2. Dec 16, 1977

    Lantheus Medical Imaging — NDA Secondary Org

  3. Dec 16, 1977

    Lantheus Medical Imaging — NDA Organization

  4. Oct 23, 1979

    Curium Pharma — NDA Secondary Org

1980s

  1. Feb 1, 1982

    General Electric — NDA Secondary Org

  2. Dec 30, 1982

    Bracco — NDA Secondary Org

2000s

  1. Nov 21, 2001

    Trace Life — Marketing Organization

  2. Nov 9, 2006

    Mallinckrodt — Marketing Organization

  3. Nov 9, 2006

    Curium Pharma — Marketing Organization

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    Radiopharmaceutical

Approval history

  • approvedPriority reviewDec 16, 1977

Chemistry & pharmacology

Loading structure…

SMILES

[201Tl+]
Mol. weight
200.97080377 g/mol
Chirality
Achiral Molecule
Inorganic
Yes
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Imaging
201-thallium

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 201tl
  • 201tl
  • thallium-201 chloride
  • thallium-201 monochloride
  • thallium (201tl) chloride
  • thallium chloride
  • thallium chloride
  • thallium chloride
  • thallium chloride (201tl) injection
  • thallium chloride, (201)tl-labeled
  • thallium chloride, (203)tl,(35)cl-labeled
  • thallium chloride, (203)tl,(37)cl-labeled
  • thallium chloride, (205)tl,(35)cl-labeled
  • thallium chloride, (205)tl,(37)cl-labeled
  • thallium(i) chloride
  • thallium(i) chloride
  • thallium monochloride
  • thallium monochloride
  • thallium monochloride
  • thallous chloride
  • thallous chloride
  • thallous chloride
  • thallous chloride
  • thallous chloride
  • thallous chloride ti 201
  • thallous chloride tl 201
  • thallous chloride tl 201
  • thallous chloride tl-201
  • thallous chloride tl-201
  • thallous chloride tl-201
  • thallous chloride tl-201
  • thallous chloride tl-201
  • thallous chloride tl-201

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00381316Phase 4Jul 1, 2006General Electric
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
General ElectricFor profit1112006
1 organizations
Page 1 / 1

Marketing (8)

OrganizationOrg typeRelationshipDate
BraccoFor profitNDA2Dec 30, 1982
Curium PharmaFor profitNDA2Oct 23, 1979
Curium PharmaFor profitMKTGNov 9, 2006
General ElectricFor profitNDA2Feb 1, 1982
Lantheus Medical ImagingFor profitNDA2Dec 16, 1977
Lantheus Medical ImagingFor profitNDADec 16, 1977
MallinckrodtFor profitMKTGNov 9, 2006
Trace LifeFor profitMKTGNov 21, 2001